MiMedx Group (MDXG) Expected to Post Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is expected to issue its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.0003 per share and revenue of $68.56 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The company had revenue of $64.36 million during the quarter, compared to analyst estimates of $63.46 million. On average, analysts expect MiMedx Group to post ($0.10) EPS for the current fiscal year and $0.17 EPS for the next fiscal year.

MiMedx Group Price Performance

MDXG opened at $4.23 on Wednesday. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.97. The company has a fifty day simple moving average of $4.56 and a 200 day simple moving average of $4.09. The stock has a market cap of $616.56 million, a P/E ratio of 105.78 and a beta of 1.18.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on MDXG shares. Craig Hallum lifted their target price on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Seaport Research Partners cut MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Raymond James Financial set a $8.00 target price on MiMedx Group in a research note on Monday, August 17th. Cantor Fitzgerald restated an “overweight” rating on shares of MiMedx Group in a report on Tuesday, September 15th. Finally, Weiss Ratings raised MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, August 27th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, MiMedx Group has a consensus rating of “Moderate Buy” and an average target price of $8.57.

MiMedx Group Company Profile

MiMedx Group, Inc is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications.

The company’s portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures.